Arcutis Biotherapeutics (Nasdaq:ARQT) - Aandelenkoers, Nieuws & Analyse

ARQT Overzicht aandelen

Arcutis Biotherapeutics, Inc. is een biofarmaceutisch bedrijf dat zich richt op de ontwikkeling en commercialisering van behandelingen voor dermatologische ziekten.

Over het bedrijf

ARQT fundamentele analyse
Sneeuwvlok Score
Waardering	5/6
Toekomstige groei	5/6
Prestaties in het verleden	0/6
Financiële gezondheid	4/6
Dividenden	0/6

Beloningen

Trading at 89.7% below our estimate of its fair value

Earnings are forecast to grow 69.11% per year

Trading at good value compared to peers and industry

Risicoanalyse

Shareholders have been diluted in the past year

Significant insider selling over the past 3 months

Arcutis Biotherapeutics, Inc. Concurrenten

POINT Biopharma Global

NasdaqCM:PNT

US$1.3b

Entrada Therapeutics

NasdaqGM:TRDA

US$619.3m

Capricor Therapeutics

NasdaqCM:CAPR

US$884.3m

Immunome

NasdaqCM:IMNM

US$701.0m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Arcutis Biotherapeutics
Historische aandelenkoersen
Huidige aandelenkoers	US$8.67
52 Week Hoogtepunt	US$13.17
52 Week Laag	US$1.76
Bèta	1.17
11 maand verandering	-13.47%
3 maanden verandering	-3.67%
1 Jaar Verandering	270.51%
33 jaar verandering	-60.47%
5 jaar verandering	n/a
Verandering sinds IPO	-60.23%

Recent nieuws en updates

Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) Business And Shares Still Trailing The Industry

Sep 23

Recent updates

Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) Business And Shares Still Trailing The Industry

Sep 23

Arcutis: Shares Plateau After Early 2024 Gains, But Further Upside Looks Likely

Aug 22

Is Arcutis Biotherapeutics (NASDAQ:ARQT) A Risky Investment?

Jul 17

Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) Popularity With Investors Is Under Threat From Overpricing

Jun 21

Analysts' Revenue Estimates For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Are Surging Higher

May 24

Arcutis Stock: Sales Expansion Momentum Puts It On A Good Trajectory

May 20

Arcutis Biotherapeutics: Betting Big On Zoryve

May 01

New Forecasts: Here's What Analysts Think The Future Holds For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)

Apr 25

Need To Know: Analysts Are Much More Bullish On Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Revenues

Mar 03

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Just Reported Yearly Earnings And Analysts Are Lifting Their Estimates

Mar 02

Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) 75% Share Price Surge Not Quite Adding Up

Feb 28

Arcutis: Slow Sales Of Zoryve May Be Painting The Wrong Picture

Jan 31

Growth Investors: Industry Analysts Just Upgraded Their Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Revenue Forecasts By 21%

Oct 23

Analysts' Revenue Estimates For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Are Surging Higher

Aug 13

Earnings Release: Here's Why Analysts Cut Their Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Price Target To US$41.57

Aug 11

Does Arcutis Biotherapeutics (NASDAQ:ARQT) Have A Healthy Balance Sheet?

May 02

Is Arcutis Biotherapeutics (NASDAQ:ARQT) A Risky Investment?

Dec 18

Rendement voor aandeelhouders

	ARQT	US Biotechs	US Markt
7D	-0.5%	-0.7%	-1.6%
1Y	270.5%	19.8%	30.8%

Rendement versus industrie: ARQT exceeded the US Biotechs industry which returned 19.8% over the past year.

Rendement versus markt: ARQT exceeded the US Market which returned 30.8% over the past year.

Prijsvolatiliteit

Is ARQT's price volatile compared to industry and market?
ARQT volatility
ARQT Average Weekly Movement	9.2%
Biotechs Industry Average Movement	9.6%
Market Average Movement	6.0%
10% most volatile stocks in US Market	14.9%
10% least volatile stocks in US Market	2.9%

Stabiele aandelenkoers: ARQT has not had significant price volatility in the past 3 months compared to the US market.

Volatiliteit in de loop van de tijd: ARQT's weekly volatility (9%) has been stable over the past year.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2016	296	Frank Watanabe	www.arcutis.com

Arcutis Biotherapeutics, Inc. is een biofarmaceutisch bedrijf dat zich toelegt op de ontwikkeling en commercialisering van behandelingen voor dermatologische aandoeningen. De belangrijkste productkandidaat is ARQ-151, een topische roflumilast crème die fase III klinische studies heeft voltooid voor de behandeling van plaque psoriasis en atopische dermatitis. Het bedrijf ontwikkelt ook ARQ-154, een topische ZORYVE voor de behandeling van hoofdhuid- en lichaams-psoriasis en seborroïsch eczeem; ARQ-252, een selectieve topische janus kinase type 1 remmer voor handeczeem en vitiligo; ARQ-255, een topische JAK1 remmer voor alopecia areata; en ARQ-234, een CD200R fusie-eiwit voor de behandeling van matige tot ernstige atopische dermatitis.

Arcutis Biotherapeutics, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Arcutis Biotherapeutics zich tot de beurswaarde?
ARQT fundamentele statistieken
Marktkapitalisatie	US$1.01b
Inkomsten(TTM)	-US$198.76m
Inkomsten(TTM)	US$132.06m

7.7x

P/S-verhouding

-5.1x

Koers/Winstverhouding

Is ARQT overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
ARQT resultatenrekening (TTM)
Inkomsten	US$132.06m
Kosten van inkomsten	US$10.15m
Brutowinst	US$121.91m
Overige uitgaven	US$320.68m
Inkomsten	-US$198.76m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

Nov 06, 2024

Winst per aandeel (EPS)	-1.70
Brutomarge	92.32%
Nettowinstmarge	-150.51%
Schuld/Eigen Vermogen Verhouding	109.3%

Hoe presteerde ARQT op de lange termijn?

Bekijk historische prestaties en vergelijking

ARQT Overzicht aandelen

Beloningen

Risicoanalyse

Arcutis Biotherapeutics, Inc. Concurrenten

NasdaqCM:PNT

US$1.3b

NasdaqGM:TRDA

US$619.3m

NasdaqCM:CAPR

US$884.3m

NasdaqCM:IMNM

US$701.0m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Arcutis Biotherapeutics, Inc. Presents Positive Patient-Reported Outcome Data for ZORYVE® (Roflumilast) Cream 0.15% in Atopic Dermatitis at American College of Allergy, Asthma and Immunology 2024 Annual Scientific Meeting

Arcutis Biotherapeutics, Inc. to Report Q3, 2024 Results on Nov 06, 2024

Arcutis Canada, Inc. Receives Regulatory Approval from Health Canada for ZORYVE Foam 0.3% to Treat Seborrheic Dermatitis in Individuals 9 Years of Age and Older

No longer forecast to breakeven

Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) Business And Shares Still Trailing The Industry

Arcutis Biotherapeutics, Inc. Announces Publication of ZORYVE (Roflumilast) Cream 0.15% Pivotal Results from Phase 3 INTEGUMENT-1 and -2 Trials in Mild to Moderate Atopic Dermatitis in Journal of American Medical Association Dermatology

Recent updates

Arcutis Biotherapeutics, Inc. Presents Positive Patient-Reported Outcome Data for ZORYVE® (Roflumilast) Cream 0.15% in Atopic Dermatitis at American College of Allergy, Asthma and Immunology 2024 Annual Scientific Meeting

Arcutis Biotherapeutics, Inc. to Report Q3, 2024 Results on Nov 06, 2024

Arcutis Canada, Inc. Receives Regulatory Approval from Health Canada for ZORYVE Foam 0.3% to Treat Seborrheic Dermatitis in Individuals 9 Years of Age and Older

No longer forecast to breakeven

Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) Business And Shares Still Trailing The Industry

Arcutis Biotherapeutics, Inc. Announces Publication of ZORYVE (Roflumilast) Cream 0.15% Pivotal Results from Phase 3 INTEGUMENT-1 and -2 Trials in Mild to Moderate Atopic Dermatitis in Journal of American Medical Association Dermatology

Arcutis Biotherapeutics, Inc. Announces Positive Long-Term Results of Roflumilast Cream 0.05% Show Durable and Improved Efficacy over Time and Favorable Safety Profile in Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis

Arcutis: Shares Plateau After Early 2024 Gains, But Further Upside Looks Likely

Consensus estimates of losses per share improve by 12%

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

President recently sold US$131k worth of stock

Forecast to breakeven in 2026

Arcutis Biotherapeutics, Inc. to Report Q2, 2024 Results on Aug 14, 2024

Arcutis Launches ZORYVE (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis

Arcutis Biotherapeutics, Inc. Submits Supplemental New Drug Application for Zoryve (Roflumilast) Foam to the FDA for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and over

Is Arcutis Biotherapeutics (NASDAQ:ARQT) A Risky Investment?

Arcutis Biotherapeutics, Inc. Announces the U.S. Food and Drug Administration's Approval of the Supplemental New Drug Application for ZORYVE (Roflumilast) Cream

Insufficient new directors

Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) Popularity With Investors Is Under Threat From Overpricing

Senior VP & Chief Medical Officer exercised options and sold US$201k worth of stock

Senior VP & Chief Medical Officer recently sold US$435k worth of stock

Senior VP & Chief Medical Officer notifies of intention to sell stock

Analysts' Revenue Estimates For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Are Surging Higher

Consensus revenue estimates increase by 36%

Arcutis Stock: Sales Expansion Momentum Puts It On A Good Trajectory

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Arcutis Biotherapeutics, Inc. Announces Journal of Clinical and Aesthetic Dermatology Publishes the Outcomes of a Comprehensive Evaluation by an Expert Dermatology

President notifies of intention to sell stock

Arcutis Biotherapeutics: Betting Big On Zoryve

Arcutis Biotherapeutics, Inc. to Report Q1, 2024 Results on May 14, 2024

Arcutis Biotherapeutics, Inc., Annual General Meeting, Jun 14, 2024

New Forecasts: Here's What Analysts Think The Future Holds For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)

Consensus revenue estimates increase by 10%

Arcutis Biotherapeutics, Inc. Announces Chief Financial Officer Changes

Arcutis Presents Late-Breaking Data from INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Atopic Dermatitis in Children Ages 2 to 5 At the American Academy of Dermatology Annual Meeting

President notifies of intention to sell stock

Consensus revenue estimates increase by 24%

Need To Know: Analysts Are Much More Bullish On Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Revenues

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Just Reported Yearly Earnings And Analysts Are Lifting Their Estimates

Arcutis Biotherapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $150.000003 million.

Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) 75% Share Price Surge Not Quite Adding Up

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Price target increased by 18% to US$13.33

Arcutis Biotherapeutics, Inc. to Report Q4, 2023 Results on Feb 27, 2024

Arcutis Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Arcutis: Slow Sales Of Zoryve May Be Painting The Wrong Picture

Arcutis Biotherapeutics, Inc. Announces New Subgroup Analysis Highlighting That Adults and Adopts ZoryVE Topical Foam, 0.3% Clears Seborrheic Dermatitis in Individuals Who Previously Reported an Inadequate Response to Topical Steroids

Arcutis Biotherapeutics, Inc. Announces New Individual Patient Response Data Showed at the 2024 Winter Clinical Dermatology Conference - Hawaii

FDA Approves Arcutis' ZORYVE®? (roflumilast) Topical Foam, 0.3% for the Treatment of Seborrheic Dermatitis in Individuals Aged 9 Years and Older

President exercised options to buy US$118k worth of stock.

Arcutis Biotherapeutics, Inc. Announces FDA Accepts Supplemental New Drug Application for Roflumilast Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to Age 6

Consensus revenue estimates increase by 19%

Growth Investors: Industry Analysts Just Upgraded Their Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Revenue Forecasts By 21%

New major risk - Shareholder dilution

Arcutis Biotherapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $99.99925 million.

New major risk - Revenue and earnings growth

Consensus revenue estimates increase by 10%

Arcutis Biotherapeutics, Inc. Presents Positive Patient-Reported Outcome Data from the Pivotal Arrector Phase 3 Trial in Scalp and Body Psoriasis At European Academy of Dermatology and Venereology (Eadv) Congress

Price target decreased by 14% to US$37.86